Production (Stage)
Heron Therapeutics, Inc.
HRTX
$2.12
$0.020.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.90M | 40.78M | 32.81M | 36.02M | 34.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.90M | 40.78M | 32.81M | 36.02M | 34.67M |
| Cost of Revenue | 10.74M | 13.41M | 13.92M | 14.95M | 13.05M |
| Gross Profit | 28.17M | 27.38M | 18.89M | 21.07M | 21.62M |
| SG&A Expenses | 25.01M | 23.20M | 23.35M | 27.52M | 26.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.75M | 36.61M | 37.27M | 42.47M | 39.47M |
| Operating Income | 3.15M | 4.17M | -4.46M | -6.45M | -4.80M |
| Income Before Tax | 2.64M | 3.66M | -4.85M | -9.24M | -3.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.64M | 3.66M | -4.85M | -9.24M | -3.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.64M | 3.66M | -4.85M | -9.24M | -3.16M |
| EBIT | 3.15M | 4.17M | -4.46M | -6.45M | -4.80M |
| EBITDA | 3.71M | 4.75M | -3.88M | -5.80M | -4.11M |
| EPS Basic | 0.02 | 0.02 | -0.03 | -0.06 | -0.02 |
| Normalized Basic EPS | 0.01 | 0.02 | -0.02 | -0.04 | -0.01 |
| EPS Diluted | 0.01 | 0.02 | -0.03 | -0.06 | -0.02 |
| Normalized Diluted EPS | 0.01 | 0.02 | -0.02 | -0.04 | -0.01 |
| Average Basic Shares Outstanding | 153.49M | 153.15M | 152.83M | 152.31M | 151.20M |
| Average Diluted Shares Outstanding | 196.92M | 153.15M | 152.83M | 152.31M | 151.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |